
Five Drug “Discounts” That Make You Pay More
Strolling La Rambla in Barcelona in August, most windows display Rebaixes (Catalan) or Rebajas (Spanish), indicating summer sales. After three blocks, these words lose meaning. In nearby neighborhoods, the same goods sell daily for less than La Rambla’s “sale” prices. Tourist shops don’t lower prices; first they inflate a lot, then subtract a little, then offer a “discount,” steering people toward a product that costs more. Real prices are available just off the main road, but few go there.
American drug pricing is La Rambla at industrial scale. Manufacturers returned $356 billion in list-price concessions on brand drugs in 2024, every intermediary announced savings, and the real price stayed hidden. This February, Congress passed the most sweeping federal PBM law ever enacted, mandating full rebate pass-through and delinking PBM pay from list prices, and the FTC reached a consent order requiring Express Scripts to base patient cost sharing on net prices.
Click to read the article on the Medhealth Outlook website.



